Neoadjuvant Opdivo With Chemotherapy Provides Benefits For Patients With Resectable Non-Small Cell Lung Cancer Across PD-L1 Expression Levels With Three-Year Follow Up In CheckMate -816 Trial
Portfolio Pulse from Benzinga Newsdesk
Bristol Myers Squibb (NYSE:BMY) announced three-year follow-up results from the Phase 3 CheckMate -816 trial, demonstrating sustained event-free survival and promising overall survival trends with three cycles of Opdivo in combination with platinum-based chemotherapy for the neoadjuvant treatment of patients with resectable non-small cell lung cancer. The results showed a greater reduction in the risk of disease recurrence, progression or death than chemotherapy alone, regardless of PD-L1 expression levels. The results will be presented at the European Society for Medical Oncology Congress 2023.
October 17, 2023 | 7:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bristol Myers Squibb's Opdivo shows promising results in Phase 3 trial, which could potentially boost the company's reputation and sales in the oncology market.
The positive results from the Phase 3 trial of Opdivo could potentially lead to increased demand for the drug, which would positively impact Bristol Myers Squibb's sales and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100